UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 20 von 5953
Datensatz exportieren als...
BibTeX
18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Clinical cancer research, 2017-03, Vol.23 (6), p.1432-1441
Quintela-Fandino, Miguel
Lluch, Ana
Manso, Luis
Calvo, Isabel
Cortes, Javier
García-Saenz, José Angel
Gil-Gil, Miguel
Martinez-Jánez, Noelia
Gonzalez-Martin, Antonio
Adrover, Encarna
de Andres, Raquel
Viñas, Gemma
Llombart-Cussac, Antonio
Alba, Emilio
Guerra, Juan
Bermejo, Begoña
Zamora, Esther
Moreno-Anton, Fernando
Pernas Simon, Sonia
Carrato, Alfredo
Lopez-Alonso, Antonio
Escudero, María José
Campo, Ruth
Carrasco, Eva
Palacios, José
Mulero, Francisca
Colomer, Ramon
2017
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Quintela-Fandino, Miguel
Lluch, Ana
Manso, Luis
Calvo, Isabel
Cortes, Javier
García-Saenz, José Angel
Gil-Gil, Miguel
Martinez-Jánez, Noelia
Gonzalez-Martin, Antonio
Adrover, Encarna
de Andres, Raquel
Viñas, Gemma
Llombart-Cussac, Antonio
Alba, Emilio
Guerra, Juan
Bermejo, Begoña
Zamora, Esther
Moreno-Anton, Fernando
Pernas Simon, Sonia
Carrato, Alfredo
Lopez-Alonso, Antonio
Escudero, María José
Campo, Ruth
Carrasco, Eva
Palacios, José
Mulero, Francisca
Colomer, Ramon
Titel
18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Ist Teil von
Clinical cancer research, 2017-03, Vol.23 (6), p.1432-1441
Ort / Verlag
Philadelphia: American Association for Cancer Research Inc
Erscheinungsjahr
2017
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
Abstract Purpose: We previously detected promising efficacy of neoadjuvant nintedanib (a multityrosine kinase inhibitor, TKI) in early HER2-negative breast cancer. In a preclinical study, we monitored stromal hypoxia with 18F-fluoromisonidazole-positron emission tomography (18F-FMISO-PET); we found that reoxygenation of tumors (or lack of it) during a window-of-opportunity (WoO) treatment with TKIs correlated with the benefit (or lack of it) from TKI-plus-chemotherapy combinations. We studied the predictive role of 18F-FMISO-PET for the TKI nintedanib in the neoadjuvant setting in a phase II WoO randomized trial. Experimental Design: Patients were randomized to a 14-day WoO of nintedanib preceded and followed by an 18F-FMISO-PET, followed by nintedanib plus weekly paclitaxel (Arm A) or an 18F-FMISO-PET followed by weekly paclitaxel (Arm B) before surgery. The endpoint was residual cancer burden (RCB). The objective was to detect the patients with no response (RCB-III) on the basis of the baseline or evolutive 18F-FMISO-PET values/changes. Results: One-hundred and thirty HER2-negative patients were randomized. Seventeen (27.9%), 34 (55.7%), and 8 (13.1%) patients had an RCB of III, II, and I/0, respectively, in Arm A. In this arm, baseline hypoxic tumors had a 4.4-fold higher chance of experiencing RCB = 3 (P = 0.036) compared with baseline normoxic tumors. Nintedanib WoO induced tumor reoxygenation in 24.5% of the patients; those not reoxygenating showed a trend toward higher chance of experiencing RCB-III (6.4-fold; P = 0.09). In Arm B, 18F-FMISO-PET lacked predictive/prognostic value. Conclusions: Baseline hypoxic tumors (measured with 18F-FMISO-PET) do not benefit from neoadjuvant nintedanib. Clin Cancer Res; 23(6); 1432–41. ©2016 AACR.
Sprache
Englisch
Identifikatoren
ISSN: 1078-0432
eISSN: 1557-3265
DOI: 10.1158/1078-0432.CCR-16-0738
Titel-ID: cdi_proquest_miscellaneous_1881750705
Format
–
Schlagworte
Breast cancer
,
Cancer
,
Chemotherapy
,
Emission analysis
,
Enzyme inhibitors
,
ErbB-2 protein
,
Experimental design
,
Hypoxia
,
Paclitaxel
,
Patients
,
Pollution monitoring
,
Positron emission
,
Positron emission tomography
,
Surgery
,
Tomography
,
Tumors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX